These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24427841)

  • 1. Retigabine: blue skin discoloration and retinal pigment abnormalities.
    Prescrire Int; 2013 Nov; 22(143):269. PubMed ID: 24427841
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events.
    Brickel N; Hewett K; Rayner K; McDonald S; De'Ath J; Daniluk J; Joshi K; Boll MC; Tiamkao S; Vorobyeva O; Cooper J
    Epilepsy Behav; 2020 Jan; 102():106580. PubMed ID: 31731109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
    Garin Shkolnik T; Feuerman H; Didkovsky E; Kaplan I; Bergman R; Pavlovsky L; Hodak E
    JAMA Dermatol; 2014 Sep; 150(9):984-9. PubMed ID: 25006968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EZOGABINE (POTIGA) MACULOPATHY.
    Zaugg BE; Bell JE; Taylor KY; Bernstein PS
    Retin Cases Brief Rep; 2017 Winter; 11(1):38-43. PubMed ID: 26909536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate.
    Beacher NG; Brodie MJ; Goodall C
    BMC Oral Health; 2015 Oct; 15(1):122. PubMed ID: 26452759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retigabine: fewer drug interactions.
    Prescrire Int; 2012 Mar; 21(125):61. PubMed ID: 22428181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients.
    Amann B; Sterr A; Vieta E; Stampfer R; Walden J; Grunze H
    J Clin Psychopharmacol; 2006 Oct; 26(5):534-6. PubMed ID: 16974202
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
    Tompson DJ; Crean CS; Reeve R; Berry NS
    Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezogabine (Potiga) toxicity.
    Med Lett Drugs Ther; 2013 Nov; 55(1430):96. PubMed ID: 24276503
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.
    Gil-Nagel A; Brodie MJ; Leroy R; Cyr T; Hall S; Castiglia M; Twomey C; VanLandingham K
    Epilepsy Res; 2012 Nov; 102(1-2):117-21. PubMed ID: 22771137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The possibility of adverse effect of Kv7-channel opener retigabine on memory processes in rats.
    Zwierzyńska E; Krupa-Burtnik A; Pietrzak B
    Epilepsy Behav; 2017 Oct; 75():170-175. PubMed ID: 28866337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezogabine (Potiga) for epilepsy.
    Med Lett Drugs Ther; 2012 Aug; 54(1397):65-7. PubMed ID: 22907178
    [No Abstract]   [Full Text] [Related]  

  • 13. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels.
    Brickel N; Gandhi P; VanLandingham K; Hammond J; DeRossett S
    Epilepsia; 2012 Apr; 53(4):606-12. PubMed ID: 22428574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
    Splinter MY
    Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.
    Porter RJ; Partiot A; Sachdeo R; Nohria V; Alves WM;
    Neurology; 2007 Apr; 68(15):1197-204. PubMed ID: 17420403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hemodialysis on pharmacokinetics of ezogabine/retigabine and its N-acetyl metabolite in patients with end stage renal disease.
    Tompson DJ; Buraglio M; Bullman J; Crean CS; Rayner K
    Curr Clin Pharmacol; 2014; 9(4):319-25. PubMed ID: 25387761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blue pseudochromhidrosis secondary to topiramate treatment.
    Castela E; Thomas P; Bronsard V; Lacour JP; Ortonne JP; Passeron T
    Acta Derm Venereol; 2009; 89(5):538-9. PubMed ID: 19734991
    [No Abstract]   [Full Text] [Related]  

  • 18. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine).
    Crean CS; Tompson DJ
    Clin Ther; 2013 Jan; 35(1):87-93. PubMed ID: 23328270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.
    Porter RJ; Burdette DE; Gil-Nagel A; Hall ST; White R; Shaikh S; DeRossett SE
    Epilepsy Res; 2012 Aug; 101(1-2):103-12. PubMed ID: 22512894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
    Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
    Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.